세계의 임상 미생물학 시장 : 제품별, 질환 영역별, 최종사용자별, 지역별 - 예측(-2030년)

The clinical microbiology market is projected to reach USD 7.34 billion by 2030, growing at a CAGR of 6.6% during the forecast period.

The clinical microbiology market is witnessing strong growth, driven by advancements in diagnostic technologies such as rapid molecular testing and laboratory automation, which enable faster & accurate detection of infectious agents. In addition, the rising global burden of infectious diseases, fueled by population growth, urbanization, and increased international travel, further accelerates the demand for advanced microbiology testing solutions.

By product, the instruments segment accounted for the largest market share in 2024.

The clinical microbiology market is segmented into instruments, reagents, and media & sera. The instruments segment accounted for the largest share of the market. This dominance is driven by several factors, including the widespread adoption of conventional laboratory instruments by researchers & academic institutions, alongside increasing industry-academia collaborations in genomic research. Additionally, molecular techniques and proteomics advancements, such as integrating microfluidics with PCR and applying nanotechnology to qPCR, are fuelling the growth.

By end user, the hospitals & diagnostic centers segment accounted for the largest share of the market in 2024.

The market is segmented by end user into hospitals & diagnostic centers, contract testing laboratories, and academic & research institutes. In 2024, the hospitals & diagnostic laboratories segment accounted for the largest market share owing to the rising establishment of hospitals, the increasing outsourcing of R&D activities to diagnostic laboratories, the increasing burden of chronic diseases, and the ability of hospitals to invest in advanced healthcare infrastructure.

Asia Pacific is projected to grow at the highest CAGR during the forecast period.

The global clinical microbiology market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, contributing to increased healthcare spending across a broader population base. Additional growth drivers include the rising incidence and prevalence of infectious diseases, the modernization of healthcare infrastructure, and the growing adoption of advanced diagnostic technologies, particularly in rural areas. These factors are anticipated to create substantial growth opportunities for clinical microbiology companies in the Asia Pacific.

The break-up of the profile of primary participants in the clinical microbiology market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in this market are bioMerieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Bruker Corporation (US), Hologic, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Siemens Healthineers AG (Germany), Shimadzu Corporation (Japan), and Neogen Corporation (US), among others.

Research Coverage:

This research report categorizes the clinical microbiology market by product (instruments, reagents, and media & sera), by disease area (respiratory diseases, bloodstream infections, gastrointestinal diseases, sexually transmitted diseases, urinary tract infections, periodontal diseases, and other diseases), by end user (hospitals & diagnostic centers, contract testing laboratories, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

Reasons To Buy This Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall clinical microbiology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (technological advancements in clinical diagnosis and novel molecular diagnostic-based instruments, rising incidence of infectious diseases and epidemics, increasing R&D programs and public-private investments), opportunities (improved healthcare infrastructure in emerging countries), restraints (limited reimbursement policies for clinical microbiology testing procedures), and challenges (operational barriers to diagnostic microbiology tests in emerging countries) influencing the growth of the clinical microbiology market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the clinical microbiology market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the clinical microbiology market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical microbiology market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like bioMerieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland), among others, in the clinical microbiology market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CLINICAL MICROBIOLOGY MARKET OVERVIEW
• 4.2 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
• 4.3 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2025 VS. 2030 (USD MILLION)
• 4.4 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.5 CLINICAL MICROBIOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Technological advancements and development of novel molecular diagnostic-based instruments
    • 5.2.1.2 Rising incidence of infectious diseases and epidemics
    • 5.2.1.3 Increasing focus on R&D programs and public-private investments
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Limited reimbursement policies for clinical microbiology testing procedures
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Improved healthcare infrastructure in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Operational barriers for diagnostic microbiology tests
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY PRODUCTS
  • 5.3.2 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY TEST KITS, BY KEY PLAYER, 2023-2025
  • 5.3.3 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY PRODUCTS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR OPTICAL MICROSCOPES
  • 5.7.2 IMPORT DATA (HS CODE 9011)
  • 5.7.3 EXPORT DATA (HS CODE 9011)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 CLINICAL MICROBIOLOGY MARKET: ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY FRAMEWORK
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
      • 5.10.1.2.3 France
      • 5.10.1.2.4 Italy
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
      • 5.10.1.5.1 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 MALDI-TOF mass spectrometry
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Optical immunosensors
    • 5.11.2.2 Electrochemical immunosensors
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Automated multiplex PCR systems
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: IMPACT OF MALDI-TOF MS AND RAPID SUSCEPTIBILITY TESTING ON SEPSIS MANAGEMENT
  • 5.16.2 CASE STUDY 2: IMPACT OF MULTIPLEX PCR PANELS IN MANAGING ACUTE GASTROENTERITIS IN ED
• 5.17 IMPACT OF AI/GENERATIVE AI IN CLINICAL MICROBIOLOGY MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI-USE CASES
  • 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
  • 5.17.5 FUTURE OF AI IN CLINICAL MICROBIOLOGY MARKET
• 5.18 TRUMP TARIFF IMPACT ON CLINICAL MICROBIOLOGY MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 KEY IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals & diagnostic centers
    • 5.18.5.2 Contract testing laboratories
    • 5.18.5.3 Academic & research institutes

6 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 INSTRUMENTS
  • 6.2.1 LABORATORY INSTRUMENTS
    • 6.2.1.1 Incubators
      • 6.2.1.1.1 Rising demand for cell culture applications to drive market
    • 6.2.1.2 Gram stainers
      • 6.2.1.2.1 Rapid, accurate screening of bacterial pathogens to fuel uptake
    • 6.2.1.3 Bacterial colony counters
      • 6.2.1.3.1 Increased focus on accurate bacterial quantification to drive market
    • 6.2.1.4 Autoclave sterilizers
      • 6.2.1.4.1 Increasing focus on infection control in healthcare facilities to support market growth
    • 6.2.1.5 Microbial air samplers
      • 6.2.1.5.1 Need for enhanced air quality monitoring in cleanrooms to accelerate segment growth
    • 6.2.1.6 Anaerobic culture systems
      • 6.2.1.6.1 Increased research on anaerobic microorganisms to boost segment growth
    • 6.2.1.7 Petri dish fillers
      • 6.2.1.7.1 Need for minimal bench space and effective control with graphical user interfaces to aid segment growth
    • 6.2.1.8 Blood culture systems
      • 6.2.1.8.1 Technological advancements in diagnostic testing to drive market
    • 6.2.1.9 Microbial culture systems
      • 6.2.1.9.1 Increase in biopharmaceutical research to augment segment growth
    • 6.2.1.10 Other laboratory instruments
  • 6.2.2 MICROBIOLOGY ANALYZERS
    • 6.2.2.1 Molecular diagnostic instruments
      • 6.2.2.1.1 Advancements in multiplexing techniques and high adoption of genomics-based analysis to aid market growth
    • 6.2.2.2 Microscopes
      • 6.2.2.2.1 Rising demand for high-resolution imaging to propel market
    • 6.2.2.3 Mass spectrometers
      • 6.2.2.3.1 Increased applications in proteomics & metabolomics to boost market
• 6.3 REAGENTS
  • 6.3.1 PATHOGEN-SPECIFIC KITS
    • 6.3.1.1 Increasing private-public initiatives for research to support market growth
  • 6.3.2 GENERAL REAGENTS
    • 6.3.2.1 Rising demand for diagnostic tests for pathogen detection to propel segment growth
• 6.4 MEDIA & SERA
  • 6.4.1 RISING DEMAND FOR STANDARDIZED CULTURE MEDIA FOR MICROBIOLOGICAL TESTING TO PROPEL MARKET

7 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA

• 7.1 INTRODUCTION
• 7.2 RESPIRATORY DISEASES
  • 7.2.1 EXPANSION OF RESPIRATORY DISEASE SURVEILLANCE PROGRAMS TO DRIVE MARKET
• 7.3 BLOODSTREAM INFECTIONS
  • 7.3.1 GROWING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS TO DRIVE MARKET
• 7.4 GASTROINTESTINAL DISEASES
  • 7.4.1 HIGH RISK OF FOOD- AND WATER-BORNE INFECTIONS TO AID MARKET
• 7.5 SEXUALLY TRANSMITTED DISEASES
  • 7.5.1 INCREASING EMPHASIS ON EARLY & EFFECTIVE DISEASE DIAGNOSIS TO BOOST DEMAND
• 7.6 URINARY TRACT INFECTIONS
  • 7.6.1 FOCUS ON PREVENTIVE CARE TO SUPPORT MARKET GROWTH
• 7.7 PERIODONTAL DISEASES
  • 7.7.1 INCREASING R&D INITIATIVES TO STUDY MICROBE-INDUCED DISEASES TO FUEL MARKET
• 7.8 OTHER DISEASES

8 CLINICAL MICROBIOLOGY MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & DIAGNOSTIC CENTERS
  • 8.2.1 INCREASING PATIENT VOLUME AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
• 8.3 CONTRACT TESTING LABORATORIES
  • 8.3.1 LOW-COST OUTSOURCING OF TESTING ACTIVITIES TO LABORATORIES TO PROPEL MARKET
• 8.4 ACADEMIC & RESEARCH INSTITUTES
  • 8.4.1 EXPANSION OF RESEARCH INITIATIVES AND FAVORABLE FUNDING INVESTMENTS TO BOOST MARKET

9 CLINICAL MICROBIOLOGY MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 9.2.2 US
    • 9.2.2.1 Increasing prevalence of infectious diseases to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Supportive government initiatives and increased research funding to boost market
• 9.3 EUROPE
  • 9.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 9.3.2 GERMANY
    • 9.3.2.1 Favorable government policies to propel market
  • 9.3.3 FRANCE
    • 9.3.3.1 Favorable healthcare reforms and investments in diagnostic infrastructure to drive market
  • 9.3.4 UK
    • 9.3.4.1 Rising acceptance of genome-based diagnostic techniques to fuel market
  • 9.3.5 ITALY
    • 9.3.5.1 Improved healthcare services and better disease surveillance to support market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Growing focus on public healthcare initiatives to augment market growth
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 9.4.2 CHINA
    • 9.4.2.1 Increasing government focus on disease prevention to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Technological advancements in diagnostic kits to fuel uptake
  • 9.4.4 INDIA
    • 9.4.4.1 High target patient population to boost demand
  • 9.4.5 SOUTH KOREA
    • 9.4.5.1 Favorable government initiatives for medical tourism to support market growth
  • 9.4.6 AUSTRALIA
    • 9.4.6.1 Favorable healthcare automation techniques to support market growth
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 9.5.2 BRAZIL
    • 9.5.2.1 Universal healthcare access to drive market
  • 9.5.3 MEXICO
    • 9.5.3.1 Increasing prevalence of HIV to drive market
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 9.6.2 KINGDOM OF SAUDI ARABIA (KSA)
    • 9.6.2.1 Increasing focus on healthcare automation to drive market
  • 9.6.3 UNITED ARAB EMIRATES (UAE)
    • 9.6.3.1 Improvements in healthcare infrastructure to support market growth
  • 9.6.4 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET
• 10.3 REVENUE SHARE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS, 2024
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Instruments footprint
    • 10.5.5.5 Disease area footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 10.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 10.7 COMPANY VALUATION & FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
  • 10.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 BIOMERIEUX
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products/Services offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product/Service launches & approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 DANAHER CORPORATION
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products/Services offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product/Service launches & approvals
      • 11.1.2.3.2 Deals
      • 11.1.2.3.3 Expansions
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 BECTON, DICKINSON AND COMPANY (BD)
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products/Services offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product/Service launches & approvals
      • 11.1.3.3.2 Deals
      • 11.1.3.3.3 Expansions
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 THERMO FISHER SCIENTIFIC INC.
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products/Services offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product/Service launches & approvals
      • 11.1.4.3.2 Deals
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 F. HOFFMANN-LA ROCHE LTD.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products/Services offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product/Service launches & approvals
      • 11.1.5.3.2 Deals
      • 11.1.5.3.3 Expansions
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 ABBOTT LABORATORIES
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products/Services offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
  • 11.1.7 AGILENT TECHNOLOGIES, INC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products/Services offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Expansions
  • 11.1.8 BRUKER CORPORATION
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products/Services offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product/Service launches & approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 HOLOGIC, INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products/Services offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product/Service launches & approvals
      • 11.1.9.3.2 Deals
  • 11.1.10 MERCK KGAA
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products/Services offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
      • 11.1.10.3.2 Expansions
  • 11.1.11 BIO-RAD LABORATORIES, INC.
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products/Services offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Deals
  • 11.1.12 QIAGEN
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products/Services offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product/Service launches
      • 11.1.12.3.2 Deals
      • 11.1.12.3.3 Expansions
  • 11.1.13 SIEMENS HEALTHINEERS AG
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products/Services offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product/Service launches
      • 11.1.13.3.2 Deals
      • 11.1.13.3.3 Expansions
• 11.2 OTHER PLAYERS
  • 11.2.1 SHIMADZU CORPORATION
  • 11.2.2 NEOGEN CORPORATION
  • 11.2.3 SEEGENE INC.
  • 11.2.4 RAPID MICRO BIOSYSTEMS, INC.
  • 11.2.5 HARDY DIAGNOSTICS
  • 11.2.6 EMSL ANALYTICAL, INC.
  • 11.2.7 LIOFILCHEM S.R.L.
  • 11.2.8 TCS BIOSCIENCES LTD.
  • 11.2.9 MEMMERT GMBH + CO.KG
  • 11.2.10 VACUTEST KIMA S.R.L
  • 11.2.11 CREATIVE DIAGNOSTICS
  • 11.2.12 DCN DX

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS